Table 1.

Participants with outcomes during active, passive, and entire follow-up

	Active intervention period (5.6 years)				Passive follow-up (additional 3.1 years)				Total follow-up (8.7 years)
	Rosuvastatin vs. placebo
	Rosuva (n = 6361)	Plac (n = 6344)	HR (95% CI)	P-value	Rosuva (n = 4696)	Plac (n = 4630)	HR (95% CI)	P-value	Rosuva (n = 6361)	Rate per 100 py	Plac (n = 6344)	Rate per 100 py	HR (95% CI)	P-value
MACE-1	235 (3.7%)	304 (4.8%)	0.76 (0.64–0.91)	0.002	146 (3.1%)	181 (3.9%)	0.80 (0.64–0.99)	0.042	378 (5.9%)	0.77	472 (7.4%)	0.98	0.79 (0.69–0.90)	0.0005
MACE-2	277 (4.4%)	363 (5.7%)	0.75 (0.64–0.88)	0.0004	173 (3.7%)	207 (4.5%)	0.83 (0.68–1.01)	0.065	440 (6.9%)	0.90	550 (8.7%)	1.15	0.79 (0.69–0.89)	0.0002
MACE-2 + angina	306 (4.8%)	393 (6.2%)	0.77 (0.66–0.89)	0.0006	177 (3.8%)	215 (4.6%)	0.81 (0.67–0.99)	0.043	471 (7.4%)	0.97	584 (9.2%)	1.22	0.79 (0.70–0.89)	0.0002
Coronary ischaemic eventsa  ,b	113 (1.8%)	148 (2.3%)	0.76 (0.59–0.97)	0.025	28 (0.6%)	51 (1.1%)	0.54 (0.34–0.86)	0.01	139 (2.2%)	0.28	191 (3.0%)	0.40	0.72 (0.58–0.90)	0.003
CV death	154 (2.4%)	171 (2.7%)	0.89 (0.72–1.11)	0.306	115 (2.5%)	128 (2.8%)	0.89 (0.69–1.15)	0.377	269 (4.7%)	0.54	299 (4.7%)	0.61	0.89 (0.76–1.05)	0.171

	BP-lowering therapyc vs. placebo
	BP (n = 6356)	Plac (n = 6349)	HR (95% CI)	P-value	BP (n = 4677)	Plac (n = 4649)	HR (95% CI)	P-value	BP (n = 6356)	Rate per 100 py	Plac (n = 6349)	Rate per 100 py	HR (95% CI)	P-value
MACE-1	260 (4.1%)	279 (4.4%)	0.93 (0.79–1.10)	0.40	169 (3.6%)	158 (3.4%)	1.07 (0.86–1.33)	0.52	419 (6.6%)	0.86	431 (6.8%)	0.89	0.97 (0.85–1.11)	0.67
MACE-2	312 (4.9%)	328 (5.2%)	0.95 (0.81–1.11)	0.51	196 (4.2%)	184 (4.0%)	1.07 (0.88–1.31)	0.51	492 (7.7%)	1.02	498 (7.8%)	1.03	0.99 (0.87–1.12)	0.84
MACE-2 + angina	335 (5.3%)	364 (5.7%)	0.92 (0.79–1.06)	0.26	203 (4.3%)	189 (4.1%)	1.08 (0.89–1.32)	0.45	522 (8.2%)	1.08	533 (8.4%)	1.11	0.98 (0.87–1.10)	0.72
Stroke	75 (1.2%)	94 (1.5%)	0.80 (0.59–1.08)	0.14	44 (0.9%)	34 (0.7%)	1.30 (0.83–2.03)	0.26	116 (1.8%)	0.24	128 (2.0%)	0.91	0.91 (0.70–1.16)	0.44
Coronary ischaemic eventsa  ,  b	120 (1.9%)	141 (2.2%)	0.85 (0.67–1.08)	0.19	36 (0.8%)	43 (0.9%)	0.84 (0.54–1.31)	0.43	154 (2.4%)	0.32	176 (2.8%)	0.36	0.87 (0.70–1.09)	0.23

	Combination therapyc vs. double placebo
	Combo (n = 3180)	Dbl Plac (n = 3168)	HR (95% CI)	P-value	Combo (n = 2539)	Dbl Plac (n = 2312)	HR (95% CI)	P-value	Combo (n = 3180)	Rate per 100 py	Dbl Plac (n = 3168)	Rate per 100 py	HR (95% CI)	P-value
MACE-1	113 (3.6%)	157 (5.0%)	0.71 (0.56–0.90)	0.005	70 (3.0%)	82 (3.5%)	0.85 (0.62–1.17)	0.32	181 (5.7%)	0.74	234 (7.4%)	0.97	0.76 (0.63–0.92)	0.006
MACE-2	136 (4.3%)	187 (5.9%)	0.72 (0.57–0.89)	0.003	83 (3.5%)	94 (4.0%)	0.88 (0.65–1.18)	0.39	214 (6.7%)	0.88	272 (8.6%)	1.13	0.77 (0.65–0.92	0.005
MACE-2 + angina	147 (4.6%)	205 (6.5%)	0.71 (0.57–0.87)	0.001	86 (3.6%)	98 (4.2%)	0.87 (0.65–1.17)	0.36	228 (7.2%)	0.94	290 (9.2%)	1.21	0.77 (0.65–0.92	0.003
Coronary ischaemic eventsa  ,b	52 (1.6%)	80 (2.5%)	0.64 (0.45–0.91)	0.013	13 (0.6%)	28 (1.2%)	0.46 (0.24–0.89)	0.02	65 (2.0%)	0.27	102 (3.2%)	0.42	0.63 (0.46–0.86)	0.004

BP, blood pressure; CI, confidence interval; CV, cardiovascular; Dbl Plac, double placebo; HR, hazard ratio; MACE-1, myocardial infarction, stroke or cardiovascular death; MACE-2, myocardial infarction, stroke, cardiovascular death, revascularization, resuscitated cardiac arrest or heart failure; Plac, placebo; py, person-years; Rosuva, rosuvastatin.

^aCoronary ischaemic events: fatal or non-fatal myocardial infarction, resuscitated cardiac arrest, angina, and revascularization.

^b Post hoc outcome.

^cBP-lowering therapy: candesartan + hydrochlorothiazide.

^dCombintion therapy: candesartan/hydrochlorothiazide + rosuvastatin.